Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder

OBJECTIVE: To assess treatment effects on Expanded Disability Status Scale (EDSS) score worsening and modified Rankin Scale (mRS) scores in the N-MOmentum trial of inebilizumab, a humanized anti-CD19 monoclonal antibody, in participants with neuromyelitis optica spectrum disorder (NMOSD). METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Marignier, Romain, Bennett, Jeffrey L., Kim, Ho Jin, Weinshenker, Brian G., Pittock, Sean J., Wingerchuk, Dean, Fujihara, Kazuko, Paul, Friedemann, Cutter, Gary R., Green, Ari J., Aktas, Orhan, Hartung, Hans-Peter, Lublin, Fred D., Williams, Ian M., Drappa, Jorn, She, Dewei, Cimbora, Daniel, Rees, William, Smith, Michael, Ratchford, John N., Katz, Eliezer, Cree, Bruce A.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054974/
https://www.ncbi.nlm.nih.gov/pubmed/33771837
http://dx.doi.org/10.1212/NXI.0000000000000978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054974/
https://www.ncbi.nlm.nih.gov/pubmed/33771837
http://dx.doi.org/10.1212/NXI.0000000000000978

Ejemplares similares